Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TACE + lenvatinib + microwave ablation
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Intra-arterial, Interstitial
01
Overview
This combination treatment regimen, investigated in the TALEM trial (NCT05555316) by Sun Yat-sen University Cancer Center, is designed for patients with large unresectable hepatocellular carcinoma (HCC) (≥7 cm). The regimen consists of modified transarterial chemoembolization using blank microspheres with low-dose chemotherapy (BMS-TACE), followed by oral administration of the multi-kinase inhibitor lenvatinib, and sequential radical microwave ablation (MWA) once downstaging is achieved. Lenvatinib targets VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT to inhibit angiogenesis and tumor cell proliferation. The TACE component typically involves lipiodol, low-dose doxorubicin, and lobaplatin. The regimen aims to convert unresectable large tumors into candidates for curative ablation, showing high objective response and downstaging rates in clinical studies.
- Other names
- BMS-TACE + lenvatinib + MWATACE combined with Lenvatinib and MWA
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)DNA
Beyond the preview
Go deeper on TACE + lenvatinib + microwave ablation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TACE + lenvatinib + microwave ablation.